Search Results
Your search for ,NOW matches 6736 pages
Showing 2801 - 2850Submit Your Research Project Applications for ASCO Research Survey Pool
ASCO’s Center for Research and Analytics (CENTRA) is now accepting research applications from ASCO members who wish to conduct member surveys for research purposes. All researchers who wish to conduct surveys of opted-in ASCO members must complete a Research Survey Pool application. The application ...
Shining Her Light: 2019 International Women Who Conquer Cancer Mentorship Award Recipient Verna Vanderpuye, MBChB
By simply reaching out to new colleagues, Verna Vanderpuye, MBChB, improved the way oncology is practiced across Africa. “It is difficult to find yourself in the [predicament] of low government support, lack of research culture, and inadequate infrastructure,” explained Dr. Vanderpuye, a senior...
ASCO Advocacy and Policy Initiatives/Activities in 2019
Nearly 20% of Americans receive their health insurance coverage through Medicaid. However, unlike Medicare and other payers, Medicaid is not federally required to cover routine care costs, such as physician visits and laboratory studies, for clinical trials. Only 12 states require this coverage,...
Multimodal Therapy for High-Risk or Locally Advanced Endometrial Cancer: Is It Any Clearer in 2019?
Endometrial cancer remains the most common gynecologic malignancy affecting women in the United States. There are over 60,000 new cases diagnosed and more than 12,000 deaths annually. Traditional management includes surgical staging, with optimal disease cytoreduction as able, and adjuvant...
Reflecting on My First National Presentation
I gave my first national presentation of my original clinical research on a topic that was to become a professional obsession: finding a cure for esophageal cancer. (Spoiler, I failed.) It was late May 1982. Writing about this now is undoubtedly predicated on my recent retirement, my desire to...
Is Implicit Bias Contributing to Time Disparities in Goals-of-Care Conversations With Minority Patients?
GUEST EDITOR Addressing the evolving needs of cancer survivors at various stages of their illness and care, Palliative Care in Oncology is guest edited by Jamie H. Von Roenn, MD, FASCO. Dr. Von Roenn is ASCO’s Vice President of Education, Science, and Professional Development. It has been well...
How to Help Terminally Ill Patients Find Peace in the Dying Process
End-of-Life Oncology is a new occasional column in The ASCO Post that will explore how to ensure the care received by terminally ill patients is in alignment with their end-of-life goals and wishes. In this inaugural installment, The ASCO Post talked with Lillie D. Shockney, RN, BS, MAS,...
2019 Nobel Prize in Physiology or Medicine Announced
Today, the Nobel Assembly at Karolinska Institutet announced its decision to award the 2019 Nobel Prize in Physiology or Medicine jointly to William G. Kaelin Jr, MD; Sir Peter J. Ratcliffe, FRS; and Gregg L. Semenza, MD, PhD, for their discoveries of how cells sense and adapt to oxygen...
Early Research on Novel Interleukin-12 Gene Therapy in Glioblastoma
Recurrent high-grade glioblastoma has a poor prognosis, with a median overall survival of 6 to 9 months. Treatment is limited, partly because immunotherapy has not yet been shown to be effective in the immunosuppressive microenvironment of this tumor. A novel treatment approach involving...
FDA Pipeline: Advances in Prostate Cancer, Urothelial Cancer, Myelofibrosis, and More
In the past few weeks, the U.S. Food and Drug Administration (FDA) has issued regulatory decisions in prostate cancer, urothelial cancer, myelofibrosis, breast cancer, pediatric brain cancer, leukemia, and skin cancer. Breakthrough Therapy Designation for Niraparib in Metastatic...
Expert Point of View: Myung-Ju Ahn, MD, and Roy Herbst, MD, PhD
Formal discussant Myung-Ju Ahn, MD, of Samsung Medical Center Sungkyunkwan University, Seoul, South Korea, said that the CASPIAN results were similar to those of IMpower133, which found that the addition of the immune checkpoint inhibitor atezolizumab to etoposide/carboplatin significantly...
Greater Consensus From Global Experts on Controversies in Prostate Cancer
In late August, experts from around the globe convened in Basel, Switzerland, at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) to discuss controversial areas related to the management of advanced prostate cancer. Although the full proceedings of the conference will be published in...
Early Research on Novel Interleukin-12 ‘Gene Therapy’ in Glioblastoma
Recurrent high-grade glioblastoma has a poor prognosis, with a median overall survival of 6 to 9 months. Treatment is limited, partly because immunotherapy has not yet been shown to be effective in the immunosuppressive microenvironment of this tumor. A novel treatment approach involving...
Is Implicit Bias Contributing to Time Disparities in Goals-of-Care Conversations With Minority Patients?
GUEST EDITOR Addressing the evolving needs of cancer survivors at various stages of their illness and care, Palliative Care in Oncology is guest edited by Jamie H. Von Roenn, MD, FASCO. Dr. Von Roenn is ASCO’s Vice President of Education, Science, and Professional Development. It has been well...
Final Results of RESONATE Trial Show Long-Term Benefit of Ibrutinib in Relapsed or Refractory CLL
After 6 years of follow-up, extended treatment with ibrutinib showed sustained progression-free survival benefit and depth of response in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), including those with high-risk genomic features,...
ESMO 2019: Men With Prostate Cancer May Avoid Postoperative Radiotherapy, Study Finds
Men with prostate cancer may be spared radiotherapy after surgery, according to late-breaking results of the RADICALS-RT trial presented by Parker et al at the European Society for Medical Oncology (ESMO) Congress 2019 (Abstract LBA49_PR). The study answers a long-standing question about whether...
Ned Sharpless, MD, Testifies Before House Subcommittee on FDA Investigation of Vaping Illnesses and Regulation of E-Cigarettes
Earlier this week, Acting Commissioner of the U.S. Food and Drug Administration (FDA) Ned Sharpless, MD, testified before the U.S. House Energy and Commerce Subcommittee on the FDA’s planned regulation of electronic nicotine delivery systems and investigation of vaping illnesses. His remarks are...
HPV-Positive Oropharyngeal Cancer Burden Rising Among White Men in the United States
White men older than age 65 will have the greatest burden of oropharyngeal cancer by the year 2030, according to Maura L. Gillison, MD, PhD, Professor and Endowed Chair at MD Anderson Cancer Center in Houston. But there is some good news, she said at the 2019 Winship Cancer Institute of Emory...
Diabetes and Cancer: Researchers Link Hyperglycemia to DNA Damage
Hyperglycemia may induce DNA damage and inhibit DNA repair, which may explain why individuals with diabetes may have an increased risk for developing cancer, according to a researcher from City of Hope, Duarte, California, who presented these findings at the American Chemical Society (ACS) Fall...
ASCO Commentary in the Journal of Geriatric Oncology Reflects on the Legacy of Arti Hurria, MD, FASCO
A new ASCO paper in the Journal of Geriatric Oncology1 fondly reflects on the impact of Arti Hurria, MD, FASCO, in improving the treatment of older adults with cancer. The article is part of a special issue honoring her work in this area. Dr. Hurria was killed in a traffic accident on November 7,...
CMS Expands Coverage of CAR T-Cell Therapy for Medicare Beneficiaries
The Centers for Medicare & Medicaid Services (CMS) released a new national coverage determination (NCD) announcing that Medicare will now cover U.S. Food and Drug Administration (FDA)-approved chimeric antigen receptor T-cell (CAR T-cell) therapy for certain patients with cancer. As outlined in ...
The Role of Primary Care Physicians in Cancer Care
As our aging population increases, so does the demand for oncology services; however, as ASCO and other organizations have pointed out, a workforce shortage of oncology care specialists looms in the not-so-distant future. Given the growing need for care models that meet this demand, a better...
Cancer Prevention and Research Institute of Texas Awards $136 Million in New Grants
The Cancer Prevention and Research Institute of Texas (CPRIT) recently awarded 71 new grants, totaling close to $136 million, to advance cancer research. This total includes 58 academic research grant awards, 10 prevention awards, and 3 product development research awards. CPRIT has now brought 181 ...
Differences By Sex in Lung Cancer Incidence and Mortality: What Is Known, and What Does It Mean?
The finding that women have a higher incidence of lung cancer than men of the same age and with the same smoking history was unexpected when it first emerged from studies in the 1990s. Just as unexpected was a subsequent finding. Even with their higher risk, women have a lower mortality and higher...
The Fight Against Breast Cancer Illustrates the Health-Care Challenges of Women in Poverty
"Of all the forms of inequality, injustice in health is the most shocking and the most inhumane….” —Dr. Martin Luther King, Jr Progress has been made in expanding access to health care for low-income populations, but the quality of care still lags behind and can result in less successful outcomes...
Finding a New Focus After Cancer
In the early fall of 2015, my daughter and I were on our way to our favorite nail salon to get picture-perfect ready for a gala later that evening at Lincoln Center for the Performing Arts in New York, when I got a call from my gynecologist saying I had “flunked my Pap test.” The Pap smear showed...
Personalizing Medicine
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Origin and Taxonomy of Mucinous Ovarian Cancer
An international study has revealed the origin of mucinous ovarian cancer, confirming that unlike other types of ovarian cancer, this cancer arises from benign and borderline precursors at the ovaries and are not extraovarian metastases. These findings were published by Cheasley et al in Nature...
Sorafenib Plus Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma
During the past decade, scientists began to test whether the addition of transarterial chemoembolization (TACE) to treatment with sorafenib could increase survival in patients with advanced hepatocellular carcinoma. Scientists from Taiwan and Japan performed the first large, national-level,...
Flaxseed
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, focus on flaxseed because...
Tumor Mutational Burden Disappoints as Biomarker for Treatment Response in Exploratory Analyses of Nonsquamous NSCLC
Tumor mutational burden failed to prove effective as a biomarker for response to chemotherapy plus checkpoint inhibitor or chemotherapy alone as first-line treatment for nonsquamous non–small cell lung cancer (NSCLC) in two different exploratory analyses of KEYNOTE trials.1,2 In both analyses,...
AACR Cancer Progress Report 2019 Released
Today, the American Association for Cancer Research (AACR) released the AACR Cancer Progress Report 2019, which highlights how research largely supported by federal investments in the National Institutes of Health (NIH) is spurring improvements in public health and innovations across the spectrum...
International Guidelines for Treatment and Prophylaxis of VTE in Patients With Cancer
The 2019 International Initiative on Thrombosis and Cancer (ITAC) has issued updated clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism (VTE) in patients with cancer. They were published by Farge et al in The Lancet Oncology. The guidelines consist of...
Targeting an Important Tumor Vulnerability With Maintenance Olaparib in Germline BRCA-Mutated Pancreatic Cancer
In the POLO trial, which is discussed in this issue of The ASCO Post, Golan and colleagues evaluated the potential benefit of maintenance olaparib after disease stability or response to a minimum of 4 months of platinum-based chemotherapy in patients with metastatic pancreatic cancer and a...
ASTRO 2019: Effect of Closure of Women’s Health Clinics From 2010 to 2013 on Cervical Cancer Screening and Detection
Following the closure of nearly 100 women’s health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer; more women were diagnosed with advanced stages of the disease; and disease mortality rates rose. Findings from a new analysis combining several...
ASTRO 2019: ORIOLE Trial: Observation vs SABR for Oligometastatic Prostate Cancer
The randomized, phase II ORIOLE trial studying the efficacy of targeted high-dose radiation for men with oligometastatic prostate cancer has shown that stereotactic ablative radiation (SABR) is an effective and safe option for patients who wish to delay hormone-suppression therapy. Data from the...
Chef Uses Flavor to Fuel Her Mother’s Appetite During Cancer Treatment
The battle against cancer is typically waged by the surgeon and oncologist, but a Lexington, Kentucky–based, award-winning restaurateur and chef discovered her role as a foot soldier when she applied her culinary skills to deal with the debilitating side effects of her mother’s lung cancer...
Oncology Communications Online: Pause and Think Before Hitting ‘Send’
The emergence of online technologies over the past few decades has fundamentally changed the way society communicates and shares information. This sea change has also had profound influence on the practice of medicine, from real-time information-sharing among colleagues, to having instant access...
Olaparib Monotherapy Improves Outcomes in BRCA-Mutated, Platinum-Sensitive Relapsed Ovarian Cancer
Compared with treatment with nonplatinum-based chemotherapy, monotherapy with the PARP (poly [ADP ribose] polymerase) inhibitor olaparib led to statistically significant and clinically relevant improvements in overall response rate and progression-free survival in women with germline...
John Hansen, MD, Transplant Expert Who Founded Volunteer Donor Registries, Dies at 76
Over the past few decades, our understanding of transplant immunology has moved from basic allograft rejection to the current molecular level that offers life-saving treatments for patients with cancer. The scientific elegance of this remarkable therapy’s arc from experimental to standard of care...
Having Cancer as a Teenager Derailed My Life Course
In 1994, I was a normal, active 15-year-old, who loved cars, sports, and rock music, especially songs from my favorite group, The Clash. In fact, it was while jubilantly dancing alone in my room to one of their tunes that I vomited into my hands, an early symptom of acute myeloid leukemia (AML). I...
Doctor, Where Art Thou?
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Steven A. Rosenberg, MD, PhD, Awarded for His Pioneering Work in Immunotherapy
The Edogawa-NICHE Committee recently announced that the 2019-Edogawa NICHE Prize has been awarded to Steven A. Rosenberg, MD, PhD, for his work in developing effective adoptive immunotherapies and genetically modified T cells. Dr. Rosenberg’s research has significantly contributed to the...
Insightful Advice From a College Advisor Leads to an Unexpected Career in Oncology
For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Tatiana M. Prowell, MD, who currently serves as Associate Professor of Oncology in the Breast Cancer Program at the Johns Hopkins Kimmel Comprehensive Cancer Center and as a Medical Officer and...
Bert Vogelstein, MD, and Irving L. Weissman, MD, Recognized for Revolutionizing Cancer Research
Two scientists, whose discoveries in stem cell and cancer cell biology have led to innovative advances in fields ranging from oncology and immunology to cancer genomics and regenerative medicine, will receive the 2019 Albany Medical Center Prize in Medicine and Biomedical Research. Bert Vogelstein, ...
Primary Central Nervous System Lymphoma: Striving for a Curative Therapy
Primary central nervous system (CNS) lymphoma is a rare type of non-Hodgkin lymphoma in which standards of care have not been well established. In light of recent insights into its pathophysiology and the emergence of novel approaches, The ASCO Post asked Tracy T. Batchelor, MD, a specialist in...
NCI Community Oncology Research Program Expands to More Sites
The National Cancer Institute (NCI) has awarded 53 grants to researchers in the NCI Community Oncology Research Program (NCORP) to conduct multisite cancer clinical trials and cancer care delivery studies in their communities. In addition to 7 research hubs, these NCI grants went to 32 community...
Update on FDA-Approved CAR T-Cell Gene Therapy for B-Cell Lymphomas
On October 18, 2017, the U.S. Food and Drug Administration (FDA) granted approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. Specifically, this treatment can be used after two or more lines of systemic therapy for diffuse...
Hey Siri, Should I Get a Medical Degree?
I received a coffee mug from a physician colleague some years ago with the tag line: “Please do not confuse your Google search with my Medical Degree.” Physicians of all stripes and colors can relate to the agony of debunking a “Dr. Google” diagnosis. However, in a fast-evolving health-care...
Stage IV Melanoma: What Current Role Should Surgery Play?
Advanced melanoma has become a different entity in the era of immunotherapy and targeted agents. Considering the potential for good outcomes from systemic therapy in advanced disease, has the role of surgery changed? Should it be offered up front or limited to patients with oligometastatic ...
